Traders were quick to buy up shares of Kronos Bio Inc. (Nasdaq:KRON) following the announcement, with the current bid sitting at $0.92/share (+6.36% implied open for sellers) at the time of writing. This move could lead to the breakout of a multi-month downtrending consolidation this stock has been stuck in since the summer.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View the original article on AllPennyStocks.com
]]>